Brain metabolism, neuropathology and neurodegeneration
Editors: Matteo Bauckneht, PhD, & Guido Rovera, M.D.
Aims and scope
EJNMMI Reports is the inclusive science journal of the EJNMMI journal family. It is a peer-reviewed open access journal, following international research integrity standards.
The editorial process of EJNMMI Reports does not focus on the extent of the advance of the submitted papers. All valid research with clinical and translational relevance in the field of Nuclear Medicine (including longer and brief reports, negative and positive results, provocative topics, data & protocol descriptors) will be considered, see formats considered below.
EJNMMI Reports publishes scientific articles that are of interest to the nuclear medicine and molecular imaging community and cover diagnostics and therapy within all subfields in this subject area. The journal aims at providing clinical as well as scientific information that is useful for all relevant imaging and clinical communities as well as allied professions.
The journal considers various article types like original research articles, brief communications on novel preliminary approaches, reports on originals, case reports, pictorial essays, reviews and educational material, guidelines published by experts from different clinical and research disciplines, editorials, and letters to the editor.
Important Note
Since January 1st, 2024 the European Journal of Hybrid Imaging changed its title and is now EJNMMI Reports. Please note that the journal has an impact factor and the impact factor 2023 is 1.7.
The impact factor is currently still found in Clarivate’s JCR/ESCI under the previous title European Journal of Hybrid Imaging. According to the definition of the impact factor the new title EJNMMI Reports will only be reflected, when published content as of 2024 is included into the impact factor calculation.
Based on that procedure the journal will have “half” an impact factor in 2025 under European Journal of Hybrid Imaging and “half” an impact factor under EJNMMI Reports.
In 2026 there will be the full impact factor under EJNMMI Reports, and no longer one for European Journal of Hybrid Imaging.
Thematic Collections: Call for Papers
Articles
-
-
[18F]AlF-PSMA-11 PET in diagnosing prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-11 PET and an exploration of dual-phase scanning
-
3D dynamic diuretic renal scintigraphy using a hybrid whole body CZT SPECT/CT camera protocol in the evaluation of acute ureteric obstruction caused by ureteric stone
-
Measure of 90Y-glass microspheres residue post-TARE using PET/CT and potential impact on tumor absorbed dose in comparison 99mTc-MAA SPECT/CT dosimetry
-
PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer
-
Non-FDG PET/CT in Diagnostic Oncology: a pictorial review
-
EANM procedural guidelines for myocardial perfusion scintigraphy using cardiac-centered gamma cameras
-
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
-
Ground glass pulmonary nodules: their significance in oncology patients and the role of computer tomography and 18F–fluorodeoxyglucose positron emission tomography
-
PET/MRI: a frontier in era of complementary hybrid imaging
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.
Check if your institution is a BMC member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
Welcome to EJNMMI Reports. The European Journal of Hybrid Imaging is now EJNMMI Reports. Publishing in this open access journal ensures that your work receives the maximum visibility. The journal publishes all scientific content that is of interest to the nuclear medicine and molecular imaging community and covers diagnostics and therapy within all subfields in this subject area.
EJNMMI Reports is a peer-reviewed journal and available in all major indexing services. The editorial process of EJNMMI Reports does not focus on the extent of the advance of the submitted papers. Rather, all technically and ethically sound research including longer and brief reports, negative and positive results, data & protocol descriptors will be considered. The journal aims for fast publication times.
An important goal is to help young physicians and scientists to start publishing their scientific materials and size up their careers.
If you have something valuable to communicate in the field of Nuclear Medicine and Molecular Imaging, also as a young researcher, maybe not yet familiar with publishing, do not hesitate, write it down, stay concise, use compelling wording and submit at https://www.editorialmanager.com/ejhi. We will ensure rapid and balanced review and effective publication and dissemination of your work.
Editor-in-Chief
Ignasi Carrió
Editor-in-Chief
The EJNMMI Journal Family and EANM Springer Award
Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There you will also find details about the annual EANM Springer Prize.
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 1.7 (for former title, European Journal of Hybrid Imaging)
5-year Journal Impact Factor: 2.0
Source Normalized Impact per Paper (SNIP): 0.510
SCImago Journal Rank (SJR): 0.479Speed 2023
Submission to first editorial decision (median days): 4
Submission to acceptance (median days): 44Usage 2023
Downloads: 205,903
Altmetric mentions: 29 -
Follow
- ISSN: 3005-074X (electronic)